NASDAQ:AMRS - Amyris Stock Price, Price Target & More

$6.34 +0.04 (+0.63 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$6.34

Today's Range$6.16 - $6.45

52-Week Range$1.86 - $9.30

Volume474,037 shs

Average Volume528,686 shs

Market Capitalization$313.08 million

P/E Ratio-2.08

Dividend YieldN/A

Beta0.13

About Amyris (NASDAQ:AMRS)

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Industrial organic chemicals

Sub-IndustryOil & Gas Refining & Marketing

SectorBasic Materials

SymbolNASDAQ:AMRS

CUSIP03236M10

Webwww.amyris.com

Phone510-450-0761

Debt

Debt-to-Equity Ratio-0.78%

Current Ratio0.92%

Quick Ratio0.82%

Price-To-Earnings

Trailing P/E Ratio-2.08

Forward P/E Ratio-10.75

P/E GrowthN/A

Sales & Book Value

Annual Sales$143.45 million

Price / Sales2.20

Cash FlowN/A

Price / CashN/A

Book Value($10.05) per share

Price / Book-0.63

Profitability

EPS (Most Recent Fiscal Year)($3.05)

Net Income$-77,390,000.00

Net Margins-53.95%

Return on EquityN/A

Return on Assets-96.89%

Miscellaneous

Employees440

Outstanding Shares49,690,000

How to Become a New Pot Stock Millionaire

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Shares of Amyris reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings data on Thursday, March, 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by $0.24. The biotechnology company earned $80.59 million during the quarter, compared to analysts' expectations of $68.14 million. The company's quarterly revenue was up 262.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) earnings per share. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Amyris.

What price target have analysts set for AMRS?

3 brokerages have issued 1-year target prices for Amyris' shares. Their forecasts range from $4.00 to $15.00. On average, they anticipate Amyris' share price to reach $9.6667 in the next year. View Analyst Ratings for Amyris.

Who are some of Amyris' key competitors?

Some companies that are related to Amyris include North American Palladium (PDL), Seabridge Gold (SA), Veritiv (VRTV), Altius Minerals (ALS), Nostrum Oil & Gas (NOG), Daqo New Energy (DQ), Dundee Precious Metals (DPM), Intrepid Potash (IPI), Capstone Mining (CS), Ciner Resources (CINR), Haynes International (HAYN), Uranium Participation (U), Athabasca Oil (ATH), Highland Gold Mining (HGM), Tyman (TYMN), Major Drilling Group International (MDI), OMNOVA Solutions (OMN) and Golden Star Resources (GSC).

Who are Amyris' key executives?

Amyris' management team includes the folowing people:

Mr. John G. Melo, Pres, CEO & Director (Age 52)
Dr. Joel R. Cherry Ph.D., Pres of R&D (Age 57)
Mr. Raffi Mark Asadorian, Consultant (Age 49)
Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
Mr. Eduardo Alvarez, Chief Operating Officer

Has Amyris been receiving favorable news coverage?

Media stories about AMRS stock have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amyris earned a media sentiment score of 0.13 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $6.34.

How big of a company is Amyris?

Amyris has a market capitalization of $313.08 million and generates $143.45 million in revenue each year. The biotechnology company earns $-77,390,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 440 workers across the globe.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]

MarketBeat Community Rating for Amyris (AMRS)

Community Ranking:		2.1 out of 5 ( )
Outperform Votes:		156 (Vote Outperform)
Underperform Votes:		214 (Vote Underperform)
Total Votes:		370

MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Amyris (NASDAQ:AMRS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Amyris in the last 12 months. Their average twelve-month price target is $9.6667, suggesting that the stock has a possible upside of 52.47%. The high price target for AMRS is $15.00 and the low price target for AMRS is $4.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.67	2.50	2.67
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$9.6667	$9.6667	$9.50	$26.3333
Price Target Upside:	52.47% upside	43.42% upside	94.67% upside	652.38% upside

Amyris (NASDAQ:AMRS) Consensus Price Target History

Price Target History for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ:AMRS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/2/2018	HC Wainwright	Reiterated Rating	Buy	$15.00	Low
3/20/2018	B. Riley	Set Price Target	Buy -> Buy	$8.00 -> $10.00	Low
11/29/2017	Cowen	Reiterated Rating	Hold	$4.00	High
1/11/2017	Rodman & Renshaw	Reiterated Rating	Buy	$60.00	N/A
9/28/2016	Singular Research	Reiterated Rating	Buy	$42.00	N/A

(Data available from 4/21/2016 forward)

Amyris (NASDAQ:AMRS) Earnings History and Estimates Chart

Earnings by Quarter for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ:AMRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.53)
2019 EPS Consensus Estimate: $0.16

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.38)	($0.38)	($0.38)
Q2 2018	1	($0.21)	($0.21)	($0.21)
Q3 2018	1	($0.11)	($0.11)	($0.11)
Q4 2018	1	$0.17	$0.17	$0.17
Q1 2019	1	($0.12)	($0.12)	($0.12)
Q2 2019	1	$0.00	$0.00	$0.00
Q3 2019	1	$0.07	$0.07	$0.07
Q4 2019	1	$0.21	$0.21	$0.21

Amyris (NASDAQ AMRS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/14/2018		($0.20)					N/A
3/15/2018	Q4 2017	$0.07	($0.17)	$68.14 million	$80.59 million	View	Listen
11/14/2017	Q3 2017	($0.77)	($0.81)	$36.30 million	$24.20 million	View	N/A
8/10/2017	Q2 2017	($1.06)	($1.41)	$23.68 million	$25.68 million	View	N/A
5/15/2017	Q1 2017	($1.35)	($1.95)	$32.30 million	$13.00 million	View	N/A
3/2/2017	Q4 2016	($0.75)	($1.50)	$38.72 million	$32.20 million	View	Listen
11/2/2016	Q316	($0.90)	($1.05)	$33.61 million	$26.50 million	View	N/A
8/4/2016	Q2	($1.80)	($0.90)	$15.23 million	$9.60 million	View	N/A
5/10/2016	Q1	($1.95)	($2.55)	$10.39 million	$8.80 million	View	Listen
3/9/2016	Q4	($1.50)	($2.40)	$32.44 million	$9.80 million	View	Listen
11/5/2015	Q315	($2.55)	($3.45)	$8.84 million	$8.60 million	View	N/A
8/6/2015	Q215	($4.65)	($7.95)	$15.66 million	$7.80 million	View	N/A
5/5/2015	Q115	($1.50)	($6.15)	$21.40 million	$7.90 million	View	N/A
2/24/2015	Q414	($3.00)	($12.60)	$20.12 million	$11.60 million	View	N/A
11/4/2014	Q314	($2.10)	($4.20)	$20.51 million	$16.34 million	View	N/A
8/7/2014	Q214	($5.55)	($5.25)	$12.36 million	$9.30 million	View	N/A
5/8/2014	Q114	($4.80)	($5.40)	$13.50 million	$17.90 million	View	N/A
2/25/2014	Q413	($3.60)	($3.90)	$18.66 million	$15.40 million	View	N/A
10/31/2013	Q313	($4.50)	($4.80)	$13.59 million	$7.00 million	View	N/A
8/8/2013	Q2 2013	($4.80)	($5.10)	$11.47 million	$10.80 million	View	N/A
4/30/2013	Q1 2013	($5.85)	($5.85)	$9.80 million	$7.87 million	View	N/A
2/19/2013	Q4 2012	($7.65)	($7.35)	$10.68 million	$5.90 million	View	N/A
11/6/2012	Q312	($9.45)	($3.30)	$10.49 million	$19.10 million	View	N/A
7/31/2012		($10.35)	($9.90)			View	N/A
5/8/2012		($11.40)	($28.20)			View	N/A
2/27/2012	Q4 2011	($12.74)	($19.51)			View	N/A
11/1/2011		($10.65)	($14.55)			View	N/A
8/2/2011		($9.45)	($14.25)			View	N/A
5/5/2011		($7.50)	($11.40)			View	N/A
2/28/2011		($7.35)	($7.65)			View	N/A
11/4/2010	Q3 2010		($57.74)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Amyris (NASDAQ:AMRS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Amyris (NASDAQ AMRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 22.27%

Insider Trading History for Amyris (NASDAQ:AMRS)

Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ AMRS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2018	John Melo	Insider	Sell	10,776	$4.68	$50,431.68	83,172
5/19/2017	Patrick Y Yang	Director	Buy	300,000	$0.29	$87,000.00	153,000
4/20/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	652,513	$0.55	$358,882.15
4/18/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	1,636,930	$0.65	$1,064,004.50
3/30/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	184,535	$0.51	$94,112.85
3/29/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	417,990	$0.51	$213,174.90
3/27/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	129,059	$0.48	$61,948.32
3/23/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	165,428	$0.48	$79,405.44
3/21/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	223,073	$0.48	$107,075.04
3/20/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	88,382	$0.49	$43,307.18
3/17/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	339,908	$0.49	$166,554.92
3/15/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	270,374	$0.46	$124,372.04
3/13/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	346,429	$0.50	$173,214.50
3/9/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	520,925	$0.46	$239,625.50
3/7/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	852,224	$0.45	$383,500.80
3/3/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	868,589	$0.49	$425,608.61
3/1/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	377,823	$0.51	$192,689.73
2/27/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	287,706	$0.52	$149,607.12
2/23/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	529,747	$0.53	$280,765.91
2/21/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	287,528	$0.56	$161,015.68
2/16/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	390,918	$0.54	$211,095.72
2/10/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	429,198	$0.51	$218,890.98
2/8/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	288,765	$0.50	$144,382.50
1/12/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	29,502	$0.81	$23,896.62
1/11/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	451,806	$0.81	$365,962.86
1/9/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	1,072,847	$0.81	$869,006.07
12/14/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	87,291	$0.80	$69,832.80
12/12/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	54,286	$0.80	$43,428.80
12/8/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	285,623	$0.81	$231,354.63
12/6/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	578,550	$0.81	$468,625.50
12/2/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	556,296	$0.84	$467,288.64
11/22/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	77,383	$0.80	$61,906.40
11/17/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	509,779	$0.81	$412,920.99
11/15/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	648,342	$0.81	$525,157.02
11/11/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	427,904	$0.81	$346,602.24
11/8/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	333,811	$0.82	$273,725.02
11/4/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	2,611,233	$0.89	$2,323,997.37
10/17/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	2,300,000	$0.83	$1,909,000.00
6/14/2016	L John Doerr	Director	Buy	200,577	$1.04	$208,600.08	15,000
10/14/2015	Energies Nouvelles Activ Total	Director	Sell	80,052	$2.36	$188,922.72	64,178,185
6/5/2015	John Melo	CEO	Sell	61,276	$2.00	$122,552.00
5/12/2015	John Melo	CEO	Sell	65,575	$2.08	$136,396.00
5/15/2014	L John Doerr	Director	Buy	172,186	$3.02	$520,001.72	9,000
5/24/2013	John Melo	CEO	Sell	24,402	$2.85	$69,545.70
3/27/2013	Thani Sheikh Abdullah Bin K Al	Director	Buy	1,533,742	$3.26	$4,999,998.92
12/24/2012	Thani Sheikh Abdullah Bin K Al	Director	Buy	3,355,704	$2.98	$9,999,997.92
8/31/2012	John Melo	CEO	Sell	668,730	$3.70	$2,474,301.00
8/31/2012	L John Doerr	Director	Buy	270,270	$3.70	$999,999.00

(Data available from 1/1/2013 forward)

Amyris (NASDAQ AMRS) News Headlines

Source:

Date	Headline
	Amyris sees a future beyond fuels www.bizjournals.com - April 20 at 8:23 AM
	Analysts Expect Amyris Inc (AMRS) Will Post Quarterly Sales of $24.12 Million www.americanbankingnews.com - April 19 at 2:50 AM
	Amyris (AMRS) vs. Its Peers Financial Contrast www.americanbankingnews.com - April 18 at 9:14 PM
	Reviewing Amyris (AMRS) and Its Peers www.americanbankingnews.com - April 18 at 9:31 AM
	Stock Review for Specialty Chemicals Investors -- Aemetis, Amyris, Axalta Coating Systems, and Delta Technology www.prnewswire.com - April 18 at 8:16 AM
	Who Really Owns Amyris Inc (NASDAQ:AMRS)? finance.yahoo.com - April 17 at 5:55 PM
	Amyris (AMRS) Lowered to "Buy" at BidaskClub www.americanbankingnews.com - April 17 at 10:29 AM
	Amyris Inc (AMRS) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - April 17 at 3:13 AM
	Amyris (AMRS) Upgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 12 at 5:09 PM
	Options Traders Expect Huge Moves in Amyris (AMRS) Stock April 10, 2018 www.zacks.com - April 10 at 5:30 PM
	Options Traders Expect Huge Moves in Amyris (AMRS) Stock finance.yahoo.com - April 10 at 5:30 PM
	Comparing Amyris (AMRS) & Its Rivals www.americanbankingnews.com - April 10 at 5:19 PM
	Contrasting Amyris (AMRS) and Its Peers www.americanbankingnews.com - April 9 at 9:19 AM
	Head to Head Analysis: Amyris (AMRS) and Its Peers www.americanbankingnews.com - April 5 at 9:30 AM
	Amyris (AMRS) Cut to "Hold" at ValuEngine www.americanbankingnews.com - April 3 at 7:34 PM
	Amyris to Present at H.C. Wainwright Global Life Sciences Investment Conference on April 9, 2018 finance.yahoo.com - April 3 at 5:35 PM
	Head-To-Head Review: Amyris (AMRS) vs. Its Rivals www.americanbankingnews.com - April 2 at 11:06 AM
	Amyris (AMRS) Earns "Buy" Rating from HC Wainwright www.americanbankingnews.com - April 2 at 8:03 AM
	Financial Contrast: Stepan (SCL) and Amyris (AMRS) www.americanbankingnews.com - March 30 at 3:24 AM
	Amyris (AMRS) Given a $10.00 Price Target by B. Riley Analysts www.americanbankingnews.com - March 24 at 12:16 PM
	Free Post Earnings Research Report: Chemours’ Quarterly Sales Jumped 19%; Turned Profitable Y-o-Y finance.yahoo.com - March 23 at 8:18 AM
	Q1 2018 EPS Estimates for Amyris Inc Decreased by Analyst (AMRS) www.americanbankingnews.com - March 22 at 9:24 AM
	B. Riley Comments on Amyris Inc's Q3 2019 Earnings (AMRS) www.americanbankingnews.com - March 21 at 1:45 PM
	UPDATE: Amyris, Inc. (AMRS) PT Raised to $10 at B.Riley/FBR - StreetInsider.com www.streetinsider.com - March 20 at 8:27 AM
	Investors Buy Large Volume of Amyris Put Options (AMRS) www.americanbankingnews.com - March 20 at 6:40 AM
	Amyris, Q4 and FYE Earnings Release, Operational Highlights, and Analysts Target finance.yahoo.com - March 19 at 5:18 PM
	Amyris (AMRS) Soars: Stock Adds 14.7% in Session finance.yahoo.com - March 19 at 5:18 PM
	Mid-Afternoon Market Update: Crude Oil Up 2%; Amyris Shares ... - Nasdaq www.nasdaq.com - March 17 at 8:25 AM
	Amyris' (AMRS) CEO John Melo on Q4 2017 Results - Earnings Call Transcript seekingalpha.com - March 16 at 6:30 PM
	Edited Transcript of AMRS earnings conference call or presentation 15-Mar-18 8:30pm GMT finance.yahoo.com - March 16 at 6:30 PM
	Here's Why Amyris Stock Jumped as Much as 28.5% Higher Today finance.yahoo.com - March 16 at 6:30 PM
	10 Stocks To Watch For March 16, 2018 - Benzinga www.benzinga.com - March 16 at 8:19 AM
	Amyris Reports Another Strong Quarter with Solid Operating ... - GlobeNewswire (press release) globenewswire.com - March 16 at 8:19 AM
	Amyris (AMRS) Posts Earnings Results, Beats Expectations By $0.54 EPS www.americanbankingnews.com - March 15 at 9:02 PM
	When Will Amyris Inc (NASDAQ:AMRS) Become Profitable? finance.yahoo.com - March 15 at 6:13 PM
	Amyris Reports Another Strong Quarter with Solid Operating Performance and 2017 Revenue of $143.4 Million up 113% over 2016 finance.yahoo.com - March 15 at 6:13 PM
	Amyris (AMRS) Upgraded at Zacks Investment Research www.americanbankingnews.com - March 13 at 4:35 PM
	Amyris (AMRS) Set to Announce Quarterly Earnings on Thursday www.americanbankingnews.com - March 8 at 1:30 AM
	Amyris (AMRS) Lowered to "Strong Sell" at ValuEngine www.americanbankingnews.com - March 5 at 12:12 AM
	With A -47.59% Earnings Drop, Is Amyris Inc’s (NASDAQ:AMRS) Performance A Concern? finance.yahoo.com - February 27 at 5:55 PM
	Amyris Q4 Earnings Preview - Seeking Alpha seekingalpha.com - February 27 at 8:18 AM
	Amyris Inc (AMRS) Expected to Post Quarterly Sales of $67.64 Million www.americanbankingnews.com - February 27 at 4:36 AM
	Amyris to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15, 2018 finance.yahoo.com - February 26 at 5:45 PM
	Amyris (AMRS) Rating Increased to Sell at ValuEngine www.americanbankingnews.com - February 23 at 10:52 PM
	Amyris (AMRS) to Release Earnings on Wednesday www.americanbankingnews.com - February 21 at 2:22 AM
	Short Interest in Amyris Inc (AMRS) Rises By 34.7% www.americanbankingnews.com - February 11 at 1:52 AM
	Zacks: Analysts Expect Amyris Inc (AMRS) Will Announce Quarterly Sales of $67.64 Million www.americanbankingnews.com - February 10 at 4:18 AM
	Zacks: Analysts Expect Amyris Inc (AMRS) to Announce $0.04 Earnings Per Share www.americanbankingnews.com - February 8 at 9:20 PM
	Amyris Aprinnova Joint Venture Launches Pharmaceutical Grade Neossance Squalane USP – Opens New Market Among FDA Regulated Products finance.yahoo.com - February 8 at 3:41 PM
	Amyris Biossance Starts 2018 with Over 300% Retail Sales Growth – Now Available Across SEPHORA Canada Stores finance.yahoo.com - February 1 at 9:32 AM

Amyris (NASDAQ:AMRS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Amyris (NASDAQ:AMRS) Income Statement, Balance Sheet and Cash Flow Statement

Amyris (NASDAQ AMRS) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff